PharmaLundensis AB Logo

PharmaLundensis AB

Develops treatments for heavy metal toxicity and serious respiratory illnesses.

PHAL | SPGR

Overview

Corporate Details

ISIN(s):
SE0003359710 (+5 more)
LEI:
54930082I88D5N3GQ506
Country:
Sweden
Address:
Scheelevägen 22, 223 63 Lund
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

PharmaLundensis AB is a pharmaceutical research company that develops treatments for diseases with significant unmet needs. The company's primary project is PHAL-501, a drug designed to bind and excrete heavy metals like mercury, lead, and cadmium from the body. PHAL-501 is intended to act within the intestine, capturing toxins before they are absorbed into the bloodstream, thus offering a potentially safe and effective treatment for heavy metal toxicity. In addition to this focus, the company is also involved in developing therapies for serious respiratory illnesses, such as chronic obstructive pulmonary disease (COPD).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all PharmaLundensis AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PharmaLundensis AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PharmaLundensis AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-11 Tord Staffan Håkan Skogvall Other Buy 2,337 1,986.45 SEK
2025-01-17 SkåneÖrnen AB Other Buy 121,700 96,143.00 SEK
2025-01-17 Tord Staffan Håkan Skogvall Other Buy 10,958 7,999.34 SEK
2024-10-14 SkåneÖrnen AB Other Buy 49,370 19,748.00 SEK
2024-10-09 Tord Staffan Håkan Skogvall Other Buy 27,936 10,336.32 SEK
2024-09-26 SkåneÖrnen AB Other Buy 63,000 29,610.00 SEK
2024-09-20 Bo Wennergren Other Buy 60,000 27,600.00 SEK

Peer Companies

Company Country Ticker View
CARTA HOLDINGS, INC. Logo
Digital marketing firm offering ad platforms and integrated solutions to empower businesses.
Japan 3688
Celyad Oncology SA Logo
Clinical-stage biotech developing CAR T therapies for solid and blood cancers.
Belgium CYAD
CENTAUR MEDIA PLC Logo
Provides business intelligence, learning, and consultancy for marketing & legal professionals.
United Kingdom CAU
Cereno Scientific AB Logo
Develops epigenetic therapies for rare cardiovascular and pulmonary diseases.
Sweden CRNO
CERES INC. Logo
Develops online media platforms connecting consumers with advertisers through a rewards system.
Japan 3696
Chabiotech Co.,Ltd. Logo
Develops cell/gene therapies and offers CDMO, biobanking, and genomics services for rare diseases.
South Korea 085660
An Ad-Tech firm providing digital marketing, SEO, social media, and creative ad solutions.
South Korea 351870
Ch. Charilaou Group Plc Logo
A tour operator selling travel packages and developing online reservation platform solutions.
Cyprus CHCH
Creates data-driven, integrated marketing and connected experiences for global brands.
South Korea 030000
Chiome Bioscience Inc. Logo
Clinical-stage biotech developing therapeutic antibodies and providing R&D services to partners.
Japan 4583

Talk to a Data Expert

Have a question? We'll get back to you promptly.